356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
oleh: Neil Berinstein, Isabelle Bence-Bruckler, Nick Forward, Pierre Laneuville, Joy Mangel, Douglas Stewart, Irina Amitai, Gail Klein, Nancy Pennell, Iran Rashedi, Kim Roos, Yogesh Bramhecha, Rebekah Conlon
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.